Mirum's liver infection drug lowers virus levels in late-stage study
MIRM•Mirum said brelovitug met the main goal of a late-stage study in chronic hepatitis delta virus, with 56% of patients on 300 milligrams and 45% on 900 milligrams showing reduced virus levels and normal liver enzyme levels at 24 weeks, versus 0% in the delayed-treatment group. The company expects peak sales of at least $1 billion and plans to submit a US marketing application in the first half of 2027.
1. Study results
Mirum Pharmaceuticals said its experimental drug brelovitug met the main goal of a late-stage study for chronic hepatitis delta virus, a liver infection affecting people already infected with hepatitis B. At 24 weeks, 56% of patients receiving 300 milligrams and 45% receiving 900 milligrams had reduced hepatitis D virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group.
2. Sales and next steps
Mirum expects brelovitug to generate peak sales of at least $1 billion. The company said the drug was well tolerated across dose groups, with a safety profile consistent with previously reported data, and expects to submit a marketing application to the US FDA in the first half of 2027. Full results will be presented at an upcoming medical congress.
